185 related articles for article (PubMed ID: 20138026)
1. A simple yeast-based system for analyzing inhibitor resistance in the human cancer drug targets Hsp90alpha/beta.
Millson SH; Prodromou C; Piper PW
Biochem Pharmacol; 2010 Jun; 79(11):1581-8. PubMed ID: 20138026
[TBL] [Abstract][Full Text] [Related]
2. Expressed as the sole Hsp90 of yeast, the alpha and beta isoforms of human Hsp90 differ with regard to their capacities for activation of certain client proteins, whereas only Hsp90beta generates sensitivity to the Hsp90 inhibitor radicicol.
Millson SH; Truman AW; Rácz A; Hu B; Panaretou B; Nuttall J; Mollapour M; Söti C; Piper PW
FEBS J; 2007 Sep; 274(17):4453-63. PubMed ID: 17681020
[TBL] [Abstract][Full Text] [Related]
3. Mutations that increase both Hsp90 ATPase activity in vitro and Hsp90 drug resistance in vivo.
Zurawska A; Urbanski J; Matuliene J; Baraniak J; Klejman MP; Filipek S; Matulis D; Bieganowski P
Biochim Biophys Acta; 2010 May; 1803(5):575-83. PubMed ID: 20226818
[TBL] [Abstract][Full Text] [Related]
4. Yeast is selectively hypersensitised to heat shock protein 90 (Hsp90)-targetting drugs with heterologous expression of the human Hsp90beta, a property that can be exploited in screens for new Hsp90 chaperone inhibitors.
Piper PW; Panaretou B; Millson SH; Truman A; Mollapour M; Pearl LH; Prodromou C
Gene; 2003 Jan; 302(1-2):165-70. PubMed ID: 12527207
[TBL] [Abstract][Full Text] [Related]
5. Client Proteins and Small Molecule Inhibitors Display Distinct Binding Preferences for Constitutive and Stress-Induced HSP90 Isoforms and Their Conformationally Restricted Mutants.
Prince TL; Kijima T; Tatokoro M; Lee S; Tsutsumi S; Yim K; Rivas C; Alarcon S; Schwartz H; Khamit-Kush K; Scroggins BT; Beebe K; Trepel JB; Neckers L
PLoS One; 2015; 10(10):e0141786. PubMed ID: 26517842
[TBL] [Abstract][Full Text] [Related]
6. Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells.
Rouhi A; Miller C; Grasedieck S; Reinhart S; Stolze B; Döhner H; Kuchenbauer F; Bullinger L; Fröhling S; Scholl C
Oncotarget; 2017 Jan; 8(5):7678-7690. PubMed ID: 28032595
[TBL] [Abstract][Full Text] [Related]
7. HSP90alpha and HSP90beta isoforms selectively modulate MHC class II antigen presentation in B cells.
Houlihan JL; Metzler JJ; Blum JS
J Immunol; 2009 Jun; 182(12):7451-8. PubMed ID: 19494268
[TBL] [Abstract][Full Text] [Related]
8. Concerted actions of multiple transcription elements confer differential transactivation of HSP90 isoforms in geldanamycin-treated 9L rat gliosarcoma cells.
Chao CC; Sun FC; Wang CH; Lo CW; Chang YS; Chang KC; Chang MD; Lai YK
J Cell Biochem; 2008 Jul; 104(4):1286-96. PubMed ID: 18320580
[TBL] [Abstract][Full Text] [Related]
9. The complementation of yeast with human or Plasmodium falciparum Hsp90 confers differential inhibitor sensitivities.
Wider D; Péli-Gulli MP; Briand PA; Tatu U; Picard D
Mol Biochem Parasitol; 2009 Apr; 164(2):147-52. PubMed ID: 19320098
[TBL] [Abstract][Full Text] [Related]
10. Blind cavefish and heat shock protein chaperones: a novel role for hsp90alpha in lens apoptosis.
Hooven TA; Yamamoto Y; Jeffery WR
Int J Dev Biol; 2004; 48(8-9):731-8. PubMed ID: 15558465
[TBL] [Abstract][Full Text] [Related]
11. Differential expression of Hsp90 isoforms in geldanamycin-treated 9L cells.
Chang YS; Lo CW; Sun FC; Chang MD; Lai YK
Biochem Biophys Res Commun; 2006 May; 344(1):37-44. PubMed ID: 16630568
[TBL] [Abstract][Full Text] [Related]
12. Acquired resistance to HSP90 inhibitor 17-AAG and increased metastatic potential are associated with MUC1 expression in colon carcinoma cells.
Liu X; Ban LL; Luo G; Li ZY; Li YF; Zhou YC; Wang XC; Jin CG; Ye JG; Ma DD; Xie Q; Huang YG
Anticancer Drugs; 2016 Jun; 27(5):417-26. PubMed ID: 26872308
[TBL] [Abstract][Full Text] [Related]
13. Organelle-specific Hsp90 inhibitors.
Seo YH
Arch Pharm Res; 2015 Sep; 38(9):1582-90. PubMed ID: 26195286
[TBL] [Abstract][Full Text] [Related]
14. Proliferation, migration, and resistance to oxidative and thermal stresses of HT1080 cells with knocked out genes encoding Hsp90α and Hsp90β.
Petrenko V; Vrublevskaya V; Bystrova M; Masulis I; Kopylova E; Skarga Y; Zhmurina M; Morenkov O
Biochem Biophys Res Commun; 2023 Sep; 674():62-68. PubMed ID: 37406487
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel.
Sawai A; Chandarlapaty S; Greulich H; Gonen M; Ye Q; Arteaga CL; Sellers W; Rosen N; Solit DB
Cancer Res; 2008 Jan; 68(2):589-96. PubMed ID: 18199556
[TBL] [Abstract][Full Text] [Related]
16. Middle domain of human Hsp90 isoforms differentially binds Aha1 in human cells and alters Hsp90 activity in yeast.
Synoradzki K; Bieganowski P
Biochim Biophys Acta; 2015 Feb; 1853(2):445-52. PubMed ID: 25486457
[TBL] [Abstract][Full Text] [Related]
17. Hsp90β positively regulates μ-opioid receptor function.
Zhang Y; Zhou P; Wang Z; Chen M; Fu F; Su R
Life Sci; 2020 Jul; 252():117676. PubMed ID: 32304763
[TBL] [Abstract][Full Text] [Related]
18. Expression and therapeutic relevance of heat-shock protein 90 in pancreatic endocrine tumors.
Mayer P; Harjung A; Breinig M; Fischer L; Ehemann V; Malz M; Scherübl H; Britsch S; Werner J; Kern MA; Bläker H; Schirmacher P; Bergmann F
Endocr Relat Cancer; 2012 Jun; 19(3):217-32. PubMed ID: 22194440
[TBL] [Abstract][Full Text] [Related]
19. Features of the Streptomyces hygroscopicus HtpG reveal how partial geldanamycin resistance can arise with mutation to the ATP binding pocket of a eukaryotic Hsp90.
Millson SH; Chua CS; Roe SM; Polier S; Solovieva S; Pearl LH; Sim TS; Prodromou C; Piper PW
FASEB J; 2011 Nov; 25(11):3828-37. PubMed ID: 21778327
[TBL] [Abstract][Full Text] [Related]
20. The Distinct Assignments for Hsp90α and Hsp90β: More Than Skin Deep.
Chang C; Tang X; Woodley DT; Chen M; Li W
Cells; 2023 Jan; 12(2):. PubMed ID: 36672211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
